About Sigilon
Sigilon is a company based in Cambridge (United States) founded in 2015 by Omid Veiseh was acquired by Lilly in June 2023.. Sigilon has raised $103.8 million across 3 funding rounds from investors including Lilly, BlackRock and Flagship Pioneering. The company has 66 employees as of December 31, 2021. Sigilon operates in a competitive market with competitors including Neurocrine, Crinetics, Zucara Therapeutics, MBX Biosciences and Amolyt Pharma, among others.
- Headquarter Cambridge, United States
- Employees 66 as on 31 Dec, 2021
- Founders Omid Veiseh
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Sigilon
Sigilon has successfully raised a total of $103.8M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $80.3 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $80.3M
-
First Round
First Round
(21 Jun 2017)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2020 | Amount | Series B - Sigilon | Valuation | CPP Investments | |
| Apr, 2018 | Amount | Series A - Sigilon | Valuation |
investors |
|
| Jun, 2017 | Amount | Series A - Sigilon | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Sigilon
Sigilon has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, BlackRock and Flagship Pioneering. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Support is provided for longevity breakthrough initiatives by Longevity Vision Holding.
|
Founded Year | Domain | Location | |
|
Life sciences-focused venture capital firm
|
Founded Year | Domain | Location | |
|
Pension fund assets are managed for sustainable long-term growth.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Sigilon
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Sigilon
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Sigilon Comparisons
Competitors of Sigilon
Sigilon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurocrine, Crinetics, Zucara Therapeutics, MBX Biosciences and Amolyt Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of endocrine-related diseases and cancers
|
|
| domain | founded_year | HQ Location |
Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes
|
|
| domain | founded_year | HQ Location |
Drugs for rare endocrine diseases are developed and advanced.
|
|
| domain | founded_year | HQ Location |
Peptide therapeutics are developed for rare endocrine and metabolic disorders.
|
|
| domain | founded_year | HQ Location |
Immune-mediated targeted therapies for cancer are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Sigilon
Frequently Asked Questions about Sigilon
When was Sigilon founded?
Sigilon was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is Sigilon located?
Sigilon is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Sigilon a funded company?
Sigilon is a funded company, having raised a total of $103.8M across 3 funding rounds to date. The company's 1st funding round was a Series A of $23.5M, raised on Jun 21, 2017.
How many employees does Sigilon have?
As of Dec 31, 2021, the latest employee count at Sigilon is 66.
What does Sigilon do?
Sigilon was founded in 2015 in Cambridge, United States, within the biotechnology sector. Therapeutics targeting chronic diseases are created using cell engineering and proprietary biocompatible materials. The Shielded Living Therapeutics (SLTx) platform is employed to address various conditions. A pipeline is maintained for rare blood disorders, lysosomal diseases, and endocrine diseases, with operations focused on therapeutic development.
Who are the top competitors of Sigilon?
Sigilon's top competitors include Crinetics, Neurocrine and Zucara Therapeutics.
Who are Sigilon's investors?
Sigilon has 5 investors. Key investors include Lilly, BlackRock, Flagship Pioneering, CPP Investments, and Longevity Vision Holding.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.